A Genome-Wide Association Study Predicts the Onset of Dysgeusia Due to Anti-cancer Drug Treatment

DOI 機関リポジトリ Web Site Web Site PubMed 参考文献13件 オープンアクセス
  • Takei Minori
    Department of Pharmaceutical Information Science, Institute of Biomedical Sciences, Tokushima University Graduate School
  • Okada Naoto
    Department of Pharmacy, Tokushima University Hospital
  • Nakamura Shingen
    Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences
  • Kagawa Kumiko
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School
  • Fujii Shiro
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School
  • Miki Hirokazu
    Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital
  • Ishizawa Keisuke
    Department of Pharmacy, Tokushima University Hospital Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School
  • Abe Masahiro
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School
  • Sato Youichi
    Department of Pharmaceutical Information Science, Institute of Biomedical Sciences, Tokushima University Graduate School

この論文をさがす

抄録

<p>Dysgeusia is a major side effect of anti-cancer drug treatment. Since dysgeusia significantly lowers the patient’s QOL, predicting and avoiding its onset in advance is desirable. Accordingly, aims of the present study were to use a genome-wide association study (GWAS) to identify genes associated with the development of dysgeusia in patients taking anti-cancer drugs and to predict the development of dysgeusia using associated single nucleotide polymorphisms (SNPs). GWAS was conducted on 76 patients admitted to the Department of Hematology, Tokushima University Hospital. Using Sanger sequencing for 23 separately collected validation samples, the top two SNPs associated with the development of dysgeusia were determined. GWAS identified rs73049478 and rs41396146 SNPs on the retinoic acid receptor beta (RARB) gene associated with dysgeusia development due to the administration of anti-cancer drugs. Evaluation of the two SNPs using 23 validation samples indicated that the accuracy rate of rs73049478 was relatively high (87.0%). Thus, the findings of the present study suggest that the rs73049478 SNP of RARB can be used to predict the onset of dysgeusia caused by the administration of anti-cancer drugs.</p>

収録刊行物

参考文献 (13)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ